TY - JOUR
T1 - Identifying the early post-HIV antibody seroconversion period
AU - Hecht, Frederick M.
AU - Wellman, Robert
AU - Busch, Michael P.
AU - Pilcher, Christopher D.
AU - Norris, Philip J.
AU - Margolick, Joseph B.
AU - Collier, Ann C.
AU - Little, Susan J.
AU - Markowitz, Martin
AU - Routy, Jean Pierre
AU - Holte, Sarah
N1 - Funding Information:
This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institute of Health (NIH) Acute Infection Early Disease Research Program (AI041531, AI 041535, AI 041535, AI 041535, AI 041536, AI 041536, AI 041536, AI041534, AI041534, AI 041534, AI041534, AI043638, and AI043638). Additional support for the data collected in this study came from NIH grants (R01 AI055343, P01 AI57005, AI071713, and AI74621); Centers for AIDS Research (CFAR) grants (AI027763, AI27767, and AI27757); General Clinical Research Center (GCRC) grant (5M01-RR00032-38); Rockefeller University General Clinical Research Center (M01-RR00102); the State of California’s University-wide AIDS Research Program (IS02-SD-701); and by Fonds de la recherche en santé du Québec, FRSQ, réseau SIDA et maladies infectieuses.
Funding Information:
This study was performed by the AIEDRP, which was funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the United States. NIAID staff provided input into the design of network data collection, which was used for this study, and reviewed the final manuscript without suggesting changes. Testing was performed for the Genetics Systems rLAV (Bio-Rad) EIA assay and the Western blot assays by the manufacturers at no charge. The BED assay was performed at CDC laboratories at no charge. Participating laboratories were not involved in data analysis.
PY - 2011/8/15
Y1 - 2011/8/15
N2 - Background. Identifying persons with recent human immunodeficiency virus (HIV) antibody seroconversion is useful for treatment, research, and prevention, but the sensitivity and specificity of tests for this purpose are uncertain. Methods. We used longitudinal specimens panels from 155 persons identified prior to HIV seroconversion to assess antibody-based methods for classifying persons as within 30, 60, or 90 days of seroconversion, including 2 incidence assays, a less-sensitive (LS) enzyme immunoassay (EIA), and the BED assay. Results. Sensitivity and specificity, respectively, for identifying persons within 30 days of seroconversion were: 34%-57% and 98%-100% for 2 standard EIAs (employing a signal-to-cutoff ≤4.0; ≥1.0 defines HIV positive), 84% and 73% for the LS-EIA (≤0.2 cutoff), 88% and 72% for the BED (≤0.2 cutoff), and 43%-58% and 98% (≤3 bands) for 2 Western blot (WB) assays. By area under the receiver operator curves, the best test for identifying persons within 30 days of seroconversion was the number of bands on the Bio-Rad WB (0.90); within 60 days, the LS-EIA and BED (both 0.85); and for persons within 90 days the BED (0.86). Conclusions. Standard EIAs, Western blots, and HIV incidence assays provide useful information for identifying persons 30 to 90 days after seroconversion.
AB - Background. Identifying persons with recent human immunodeficiency virus (HIV) antibody seroconversion is useful for treatment, research, and prevention, but the sensitivity and specificity of tests for this purpose are uncertain. Methods. We used longitudinal specimens panels from 155 persons identified prior to HIV seroconversion to assess antibody-based methods for classifying persons as within 30, 60, or 90 days of seroconversion, including 2 incidence assays, a less-sensitive (LS) enzyme immunoassay (EIA), and the BED assay. Results. Sensitivity and specificity, respectively, for identifying persons within 30 days of seroconversion were: 34%-57% and 98%-100% for 2 standard EIAs (employing a signal-to-cutoff ≤4.0; ≥1.0 defines HIV positive), 84% and 73% for the LS-EIA (≤0.2 cutoff), 88% and 72% for the BED (≤0.2 cutoff), and 43%-58% and 98% (≤3 bands) for 2 Western blot (WB) assays. By area under the receiver operator curves, the best test for identifying persons within 30 days of seroconversion was the number of bands on the Bio-Rad WB (0.90); within 60 days, the LS-EIA and BED (both 0.85); and for persons within 90 days the BED (0.86). Conclusions. Standard EIAs, Western blots, and HIV incidence assays provide useful information for identifying persons 30 to 90 days after seroconversion.
UR - http://www.scopus.com/inward/record.url?scp=79960886885&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960886885&partnerID=8YFLogxK
U2 - 10.1093/infdis/jir304
DO - 10.1093/infdis/jir304
M3 - Article
C2 - 21791654
AN - SCOPUS:79960886885
SN - 0022-1899
VL - 204
SP - 526
EP - 533
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 4
ER -